Combined cell-free DNA and RNA profiling of androgen receptor in prostate cancer

Investigating cfRNA in addition to cfDNA in prostate cancers enables detection of AR (androgen receptor) splicing events and novel fusions that are not seen at the DNA level. 


Holistic molecular profiling in prostate cancer

cfDNA and cfRNA variant detection

Predicine has developed a blood and urine-based liquid biopsy to provide a simultaneous multi-parametric profiling of cfRNA and cfDNA in prostate cancer. 

cfRNA-based gene fusions and splicing variants detection

  • Detects RNA-specific splicing variants (AR-V7).
  • Detects known and novel gene fusions.

Actionable insights

  • Custom-built cfDNA and cfRNA monitoring assay to support optimal cancer treatment planning in oncology.
  • Identifies tumor mutations at the source, enabling highly accurate monitoring of disease over time.

In clinical studies, Predicine's cfDNA assays show high performance across multiple tumor types

Comparable performance between Predicine and Guardant Health's cfDNA platforms

cfDNA: Predicine vs Guardant

An independent study reports a comparable performance between Predicine and Guardant Health’s cfDNA platforms, demonstrating additional prognostic value of Predicine’s cfDNA assay related to treatment benefit and overall survival.

Study from Northwestern Univeristy.

View publication

Molecular heat map of mCRPC

cfDNA profiling in mHSPC & mCRPC

A study using Predicine’s assay on cfDNA and germline DNA to characterize alterations in prostate cancer patients and reports that somatic cfDNA alterations have potential prognositc, predictive, and therapeutic implications in metastatic prostate cancer management.  

Collaboration with Mayo Clinic

View publication

cfDNA and cfRNA-based AR profiling

An independent study reports Predicine’s assay is capable of simultaneously detecting AR alterations in cfDNA and cfRNA. Concurrent profiling of cfDNA and cfRNA may provide vital insights into disease biology and resistance mechanisms in mCRPC.

Collaboration with Monash University

In press

TMB assessment: blood vs. tissue

Comparison of TMB assessment using Predicine’s cfDNA liquid biopsy approach vs. FFPE  for molecular characterization in advanced colorectal cancer.

Collaboration with Merck and EMD Serono.

View poster

cfDNA-based copy number loss detection

Validation of Predicine cfDNA assay that detects copy number loss (CNL) in addition to copy number gain (CNG),  SNV, Indel, and rearrangement in blood and urine. 

View poster

Clinical application of cfDNA + cfRNA test

Currently, Predicine’s cfDNA and cfRNA assays are used in Phase I-III trials in US, EU, and APAC (including China). 

cfDNA and cfRNA assays

Biology-oriented liquid biopsy solutions to support clinical trials



• 600 genes
• TMB and MSI status
• Variant profiling

View test
Targeted therapy



• 152 genes
• Biomarkers related to 80+ FDA Approved Targeted Therapies
• Includes copy number loss/gain

View test
Precision medicine



• Indication specific
• Ultra-sensitive variant detection
• Superior to amplicon-based assay

Contact us to learn more

How it works

10 days turnaround

How much blood is required for the test?

Plasma (2-4ml)
Whole blood (4-10ml)

What other specimen types are compatible with Predicine NGS test?

Urine (40ml)
FFPE (10 slides; 25 mm² surface size; 20% tumor content)

Where is Predicine's laboratory located?

Predicine’s laboratory is located at Hayward (San Francisco Bay Area) in California.

Is Predicine's laboratory CLIA-certified and CAP-accredited?

Predicine’s laboratory is both CLIA-certified and CAP-accredited. See Predicine’s list of certifications at

What is the turnaround time?

10 days.

Which phases of clinical trials do you support?

Currently, Predicine is working with leading pharma to support global clinical trials from Phase I to III. Patient samples are shipped to Predicine’s laboratory from trial sites in US, EU, and APAC (including China).

Do you test clinical trial samples from US, EU, and China?

Yes. Patient samples collected at trial sites in US, EU, and APAC are shipped to Predicine’s laboratory in Hayward, CA. Patient samples collected at trial sites in China are shipped to Predicine’s laboratory in Shanghai, China.

Questions? Contact us.

If you have any questions or want additional information, please reach out to us.  We will get back to you within 24 hours.